Pembrolizumab for Non-Hodgkin's Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Non-Hodgkin's Lymphoma+1 MorePembrolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new immunotherapy drug for people with a certain type of lymphoma that has come back or didn't respond to other treatment.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 5 years

2 years
Duration of response (DOR) to pembrolizumab treatment
Overall response rate (ORR) to pembrolizumab treatment compared to historical controls.
Progression-free survival (PFS)
5 years
Overall survival (OS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Pembrolizumab Second Course
100%Parkinsonism
100%Urinary tract infection
100%Inappropriate antidiuretic hormone secretion
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab Second Course ARM group. Side effects include: Parkinsonism with 100%, Urinary tract infection with 100%, Inappropriate antidiuretic hormone secretion with 100%.

Trial Design

1 Treatment Group

Pembrolizumab Treatment
1 of 1

Experimental Treatment

29 Total Participants · 1 Treatment Group

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2

Pembrolizumab Treatment
Drug
Experimental Group · 1 Intervention: Pembrolizumab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

University of ChicagoLead Sponsor
927 Previous Clinical Trials
753,983 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,681 Previous Clinical Trials
4,957,422 Total Patients Enrolled
Justin Kline, MDPrincipal InvestigatorUniversity of Chicago
2 Previous Clinical Trials
77 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Participants must have archived biopsy material (ideally to be performed shortly before enrollment at the time of most recent relapse) for PD-L1 FISH and correlative studies.
A positive PD-L1 FISH assay in lymphoma cells indicates a PD-L1 gene alteration.
You provide informed consent for the trial.